Survival significance of epidermal growth factor receptor tyrosine kinase inhibitors and current staging system for survival after recurrence in patients with completely resected lung adenocarcinoma

References

• YoshinoIYohenaTKitajimaMSurvival of non-small cell lung cancer patients with postoperative recurrence at distant organsAnn Thorac Cardiovasc Surg20017420420911578260
   PubMedGoogle Scholar
• HungJJHsuWHHsiehCCPost-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrenceThorax200964319219619252018
   PubMedGoogle Scholar
• HungJJJengWJHsuWHPrognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasisThorax201065324124520335294
   PubMedGoogle Scholar
• ShimadaYSajiHYoshidaKPrognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancerChest201314361626163423348916
   PubMedGoogle Scholar
• KudoYShimadaYSajiHPrognostic factors for survival after recurrence in patients with completely resected lung adenocarcinoma: important roles of epidermal growth factor receptor mutation status and the current staging systemClin Lung Cancer2015166e213e22125986624
   PubMed Web of Science ®Google Scholar
• SugimuraHNicholsFCYangPSurvival after recurrent nonsmall-cell lung cancer after complete pulmonary resectionAnn Thorac Surg2007832409417 discussioin 417–41817257962
   PubMedGoogle Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• International Agency for Research on CancerTravisWDBrambillaEBurkeAMarxANicholsonAGWHO Classification of Tumours of the Lung, Pleura, Thymus and Heart4th edGeneva, SwitzerlandWorld Health Organization2015
   Google Scholar
• SobinLHGospodarowiczMKWittekindCInternational Union against Cancer, ebrary IncTNM Classification of Malignant Tumours7th edChichester, West Sussex, UK; Hoboken, NJWiley-Blackwell2009 Available from: http://site.ebrary.com/lib/yale/Doc?id=10342913Accessed June 10, 2017
   Google Scholar
• EberhardDAJohnsonBEAmlerLCMutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibJ Clin Oncol200523255900590916043828
   PubMed Web of Science ®Google Scholar
• WilliamsBASugimuraHEndoCPredicting postrecurrence survival among completely resected nonsmall-cell lung cancer patientsAnn Thorac Surg20068131021102716488713
   PubMedGoogle Scholar
• NakagawaTOkumuraNOhataKIgaiHMatsuokaTKameyamaKPostrecurrence survival in patients with stage I non-small cell lung cancerEur J Cardiothorac Surg200834349950418579404
   PubMedGoogle Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• ReckMRodriguez-AbreuDRobinsonAGKEYNOTE-024 InvestigatorsPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med2016375191823183327718847
   PubMed Web of Science ®Google Scholar
• OkamiJTaniguchiKHigashiyamaMPrognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancerOncology2007723–423424218176089
   PubMedGoogle Scholar
• SaishoSYasudaKMaedaAPost-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapyInteract Cardiovasc Thorac Surg201316216617223143203
   PubMed Web of Science ®Google Scholar
• JeonJHKangCHKimHSSeongYWParkIKKimYTPrognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resectionEur J Cardiothorac Surg201547355656224760387
   PubMed Web of Science ®Google Scholar
• SonobeMYamadaTSatoMIdentification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancerAnn Surg Oncol20142182546255424633668
   PubMedGoogle Scholar
• TakenakaTTakenoyamaMYamaguchiMImpact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancerEur J Cardiothorac Surg201547355055524894095
   PubMed Web of Science ®Google Scholar
• JiangHOverview of gefitinib in non-small cell lung cancer: an Asian perspectiveJpn J Clin Oncol200939313715019088154
   PubMed Web of Science ®Google Scholar
• IzarBSequistLLeeMThe impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancersAnn Thorac Surg201396396296823932319
   PubMed Web of Science ®Google Scholar
• KosakaTYatabeYOnozatoRKuwanoHMitsudomiTPrognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinomaJ Thorac Oncol200941222919096302
   PubMed Web of Science ®Google Scholar
• MarksJLBroderickSZhouQPrognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinomaJ Thorac Oncol20083211111618303429
   PubMed Web of Science ®Google Scholar
• KimYTSeongYWJungYJThe presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancerJ Thorac Oncol20138217117823287850
   PubMed Web of Science ®Google Scholar
• YangJCWuYLSchulerMAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol201516214115125589191
   PubMed Web of Science ®Google Scholar